Job title: Executive Vice President, Research & Development
At Lundbeck Johan is overseeing drug discovery and drug development functions, including medical affairs and is focusing on expanding Lundbeck’s pipeline of transformative medicines for brain diseases across all clinical phases through external and internal innovation.
Before joining Lundbeck, Johan was SVP & Head of Clinical Development, Neurology Business Group, at Eisai Pharmaceuticals, where he engaged in programs from preclinical development to Phase 4 studies with current programs in Alzheimer’s disease and other dementing disorders, such as dementia with Lewy bodies, epilepsy, sleep disorders and obesity. Prior to Eisai, Johan was VP at Merck Inc leading translational medicine and biomarker activities in neuroscience. Before then, Johan was CEO at GeNeuro SA, Geneva, during its build-up phase, and SVP & Therapy Area Head of Neurology, Immunology & Inflammation Research at MerckSerono S.A, Geneva. Johan began his pharmaceutical career in 1991 at Astra/AstraZeneca, Sweden, where he held various R&D leadership positions in both discovery and early development.
Johan studied medicine and dentistry at the Karolinska Institute, Stockholm. In parallel with clinical practice, he obtained a Ph.D in Neurobiology in 1989. He continued as a research fellow in Pharmacology & Psychiatry at the University of Colorado. Johan was subsequently appointed associate professor in Neurobiology at Karolinska Institute and professor in Pharmacology at the University of Chile, Santiago. He obtained business training at SIMI, Copenhagen and Thunderbird & MIT/Sloan Management Institute, Cambridge, MA.
Johan has published ~100 peer-reviewed scientific papers. During his years in industry, Johan has been engaged in numerous public-private pre-competitive consortia efforts and acts as a reviewer for funding agencies and scientific journals.
Session Q&A 12:00 pm
Ask the expert speakers from this session all your burning questionsRead more
day: Day Two
Early Decisions in Neuroscience Drug Development – Let the Molecules Speak 11:00 am
day: Day Two